ABI
HALO icon

Adamant Biomedical Investments’s Halozyme HALO Stock Holding History

Adamant Biomedical Investments’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$579K Hold
60,000
– – 0.14% 90
2014
Q3 		$546K Buy
+60,000
New +$571K 0.14% 86

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Adamant Biomedical Investments's HALO Position: Q4 2014 in Review

Adamant Biomedical Investments held its Halozyme (HALO) position steady in Q4 2014 at 60,000 shares worth $579K. The position accounts for 0.14% of the portfolio, ranked #90.

Adamant Biomedical Investments first reported a position in HALO in Q3 2014 and has held it in 2 quarters since. 132 funds tracked by Wall St. Rank hold HALO as of Q4 2014.

  • Adamant Biomedical Investments held 60,000 shares of Halozyme worth $579K as of Q4 2014.
  • Adamant Biomedical Investments left its Halozyme share count unchanged in Q4 2014.
  • Halozyme made up 0.14% of Adamant Biomedical Investments's portfolio in Q4 2014, its #90 holding.
  • Adamant Biomedical Investments first reported a position in Halozyme in Q3 2014 and has held it in 2 quarters since.
  • 132 funds tracked by Wall St. Rank held Halozyme as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.